-
Je něco špatně v tomto záznamu ?
Endothelin A receptor blocker atrasentan lowers blood pressure by the reduction of nifedipine-sensitive calcium influx in Ren-2 transgenic rats fed a high-salt diet
I. Vaněčková, Z. Dobešová, J. Kuneš, Z. Vernerová, J. Zicha,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- antagonisté endotelinového receptoru A chemie MeSH
- antihypertenziva chemie MeSH
- hypertenze patofyziologie MeSH
- kaptopril chemie MeSH
- krevní tlak fyziologie MeSH
- krmivo pro zvířata MeSH
- krysa rodu rattus MeSH
- kuchyňská sůl farmakologie MeSH
- NG-nitroargininmethylester chemie MeSH
- nifedipin chemie MeSH
- oxid dusnatý metabolismus MeSH
- pentoliniumtartrát chemie MeSH
- potkani Sprague-Dawley MeSH
- potkani transgenní MeSH
- pyrrolidiny terapeutické užití MeSH
- renin-angiotensin systém účinky léků MeSH
- renin genetika MeSH
- sympatický nervový systém patofyziologie MeSH
- synthasa oxidu dusnatého metabolismus MeSH
- vápník chemie metabolismus MeSH
- vápníkové kanály - typ L metabolismus MeSH
- vazodilatace účinky léků MeSH
- vazokonstrikce účinky léků MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
BACKGROUND: Our previous experiments demonstrated that selective endothelin A (ETA) receptor blockade had antihypertensive effects in Ren-2 transgenic rats (TGRs), but the mechanisms responsible for this change of blood pressure (BP) have not been explored yet. METHOD: Four-week-old male heterozygous TGRs and their normotensive controls--Hannover Sprague-Dawley (HanSD) rats--were fed high-salt diet (2% NaCl) and were treated with selective ETA receptor blocker atrasentan (5 mg/kg per day) for 8 weeks. At the end of the study, the contribution of principle vasoactive systems was evaluated by the sequential blockade of the renin-angiotensin system (captopril), sympathetic nervous system (pentolinium) and nitric oxide synthase [N-nitro-L-arginine methyl ester (L-NAME)]. The role of calcium influx through L-type voltage-dependent calcium channels in BP maintenance was evaluated using nifedipine. In a separate group of animals, the efficiency of distinct vasodilator systems--prostanoids (blocked by nonselective cyclooxygenase inhibitor indomethacin) and Ca-activated K channels (inhibited by tetraethylammonium)--was also analyzed. RESULTS: Atrasentan attenuated the development of hypertension in heterozygous TGRs, but had no effects in Hannover Sprague-Dawley rats. Moreover, atrasentan moderately attenuated renin-angiotensin system-dependent vasoconstriction, whereas it had no effect on sympathetic vasoconstriction. The nifedipine-sensitive BP component was markedly decreased by atrasentan treatment. In contrast, vasodilatation mediated by nitric oxide, endogenous prostanoids or Ca-activated K channels was reduced in atrasentan-treated TGRs, indicating the absence of compensatory augmentation of endothelin B receptor-mediated vasodilation in these animals. CONCLUSION: BP-lowering effect of chronic atrasentan treatment in TGRs was mainly caused by reduced Ca influx through L-type voltage-dependent calcium channels due to missing ETA receptor-dependent vasoconstriction and attenuated angiotensin II-dependent vasoconstriction.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16010735
- 003
- CZ-PrNML
- 005
- 20160414123624.0
- 007
- ta
- 008
- 160408s2015 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/HJH.0000000000000357 $2 doi
- 024 7_
- $a 10.1097/HJH.0000000000000357 $2 doi
- 035 __
- $a (PubMed)25255392
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Vaněčková, Ivana $u aInstitute of Physiology, Academy of Sciences of the Czech Republic bDepartment of Pathology, 3rd Faculty of Medicine, Charles University, Prague, Czech Republic.
- 245 10
- $a Endothelin A receptor blocker atrasentan lowers blood pressure by the reduction of nifedipine-sensitive calcium influx in Ren-2 transgenic rats fed a high-salt diet / $c I. Vaněčková, Z. Dobešová, J. Kuneš, Z. Vernerová, J. Zicha,
- 520 9_
- $a BACKGROUND: Our previous experiments demonstrated that selective endothelin A (ETA) receptor blockade had antihypertensive effects in Ren-2 transgenic rats (TGRs), but the mechanisms responsible for this change of blood pressure (BP) have not been explored yet. METHOD: Four-week-old male heterozygous TGRs and their normotensive controls--Hannover Sprague-Dawley (HanSD) rats--were fed high-salt diet (2% NaCl) and were treated with selective ETA receptor blocker atrasentan (5 mg/kg per day) for 8 weeks. At the end of the study, the contribution of principle vasoactive systems was evaluated by the sequential blockade of the renin-angiotensin system (captopril), sympathetic nervous system (pentolinium) and nitric oxide synthase [N-nitro-L-arginine methyl ester (L-NAME)]. The role of calcium influx through L-type voltage-dependent calcium channels in BP maintenance was evaluated using nifedipine. In a separate group of animals, the efficiency of distinct vasodilator systems--prostanoids (blocked by nonselective cyclooxygenase inhibitor indomethacin) and Ca-activated K channels (inhibited by tetraethylammonium)--was also analyzed. RESULTS: Atrasentan attenuated the development of hypertension in heterozygous TGRs, but had no effects in Hannover Sprague-Dawley rats. Moreover, atrasentan moderately attenuated renin-angiotensin system-dependent vasoconstriction, whereas it had no effect on sympathetic vasoconstriction. The nifedipine-sensitive BP component was markedly decreased by atrasentan treatment. In contrast, vasodilatation mediated by nitric oxide, endogenous prostanoids or Ca-activated K channels was reduced in atrasentan-treated TGRs, indicating the absence of compensatory augmentation of endothelin B receptor-mediated vasodilation in these animals. CONCLUSION: BP-lowering effect of chronic atrasentan treatment in TGRs was mainly caused by reduced Ca influx through L-type voltage-dependent calcium channels due to missing ETA receptor-dependent vasoconstriction and attenuated angiotensin II-dependent vasoconstriction.
- 650 _2
- $a krmivo pro zvířata $7 D000821
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antihypertenziva $x chemie $7 D000959
- 650 _2
- $a krevní tlak $x fyziologie $7 D001794
- 650 _2
- $a vápník $x chemie $x metabolismus $7 D002118
- 650 _2
- $a vápníkové kanály - typ L $x metabolismus $7 D020746
- 650 _2
- $a kaptopril $x chemie $7 D002216
- 650 _2
- $a antagonisté endotelinového receptoru A $x chemie $7 D065130
- 650 _2
- $a hypertenze $x patofyziologie $7 D006973
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a NG-nitroargininmethylester $x chemie $7 D019331
- 650 _2
- $a nifedipin $x chemie $7 D009543
- 650 _2
- $a oxid dusnatý $x metabolismus $7 D009569
- 650 _2
- $a synthasa oxidu dusnatého $x metabolismus $7 D019001
- 650 _2
- $a pentoliniumtartrát $x chemie $7 D010425
- 650 _2
- $a pyrrolidiny $x terapeutické užití $7 D011759
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Sprague-Dawley $7 D017207
- 650 _2
- $a potkani transgenní $7 D055647
- 650 _2
- $a renin $x genetika $7 D012083
- 650 _2
- $a renin-angiotensin systém $x účinky léků $7 D012084
- 650 _2
- $a kuchyňská sůl $x farmakologie $7 D017673
- 650 _2
- $a sympatický nervový systém $x patofyziologie $7 D013564
- 650 _2
- $a vazokonstrikce $x účinky léků $7 D014661
- 650 _2
- $a vazodilatace $x účinky léků $7 D014664
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Dobešová, Zdenka
- 700 1_
- $a Kuneš, Jaroslav
- 700 1_
- $a Vernerová, Zdenka
- 700 1_
- $a Zicha, Josef
- 773 0_
- $w MED00002723 $t Journal of hypertension $x 1473-5598 $g Roč. 33, č. 1 (2015), s. 161-9
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25255392 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160408 $b ABA008
- 991 __
- $a 20160414123708 $b ABA008
- 999 __
- $a ok $b bmc $g 1114164 $s 935103
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 33 $c 1 $d 161-9 $i 1473-5598 $m Journal of hypertension $n J Hypertens $x MED00002723
- LZP __
- $a Pubmed-20160408